Combination Therapy of Lexapro and Plavix

Introduction to Bleeding Risk

The American College of Cardiology recommends careful monitoring when using Lexapro (escitalopram) and Plavix (clopidogrel) together due to increased bleeding risk from the additive antiplatelet effects of SSRIs with clopidogrel 1

Patients with a history of gastrointestinal bleeding or peptic ulcer disease should be evaluated for baseline bleeding risk factors before proceeding with combination therapy 1
Age greater than 75 years is a risk factor for bleeding when using Lexapro and Plavix together 1
Renal impairment is a risk factor for bleeding when using Lexapro and Plavix together 1
Concurrent use of anticoagulants (triple therapy) increases the risk of bleeding when using Lexapro and Plavix together 1
Multiple comorbidities in elderly patients increase the risk of bleeding when using Lexapro and Plavix together 1

A proton pump inhibitor (PPI) should be added for gastroprotection, but omeprazole or esomeprazole should be avoided due to their inhibition of CYP2C19, which can reduce clopidogrel's antiplatelet effectiveness 1
Pantoprazole, dexlansoprazole, or lansoprazole can be used instead to maintain clopidogrel's efficacy while providing gastric protection 1

Patients should be counseled to immediately report any signs of bleeding, including melena (black, tarry stools) 2
The European Society of Cardiology recommends regular monitoring for bleeding signs throughout the duration of combination therapy, with a time-limited duration of clopidogrel therapy based on the clinical indication (typically 1-12 months post-stent) 2, 3

Alternative antidepressants with less effect on platelet function, such as mirtazapine or bupropion, should be considered if bleeding risk is particularly high 1